Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Vir Biotechnology, Inc. clinical trials
The registry lists 22 studies whose lead sponsor is Vir Biotechnology, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.
Keep track of what changes. Save the Vir Biotechnology, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Vir Biotechnology, Inc..
- Vir Biotechnology, Inc.22 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersRecruitingNCT05356741Phase 1/2
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06960395Phase 1
- A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218CompletedNCT05844228Phase 1
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434CompletedNCT05484206Phase 1
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideActive, not recruitingNCT07128550Phase 3
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.Active, not recruitingNCT05461170Phase 2
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionCompletedNCT04856085Phase 2
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionCompletedNCT04412863Phase 2
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionActive, not recruitingNCT06903338Phase 3
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B InfectionCompletedNCT05612581Phase 1/2
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionActive, not recruitingNCT07142811Phase 2
- Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus InfectionCompletedNCT04423393Phase 1
- Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)TerminatedNCT05280717Phase 1
- A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza ATerminatedNCT05567783Phase 2
- A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian ParticipantsCompletedNCT04988152Phase 1
- Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.TerminatedNCT04913675Phase 3
- Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19CompletedNCT04779879Phase 2
- VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy VolunteersCompletedNCT04725877Phase 1
- Sotrovimab Expanded Access Treatment Protocol (COVID-19)No longer availableNCT05235347
- VIR-7831 for the Early Treatment of COVID-19 in OutpatientsCompletedNCT04545060Phase 2/3
- Study of VIR-2482 in Healthy VolunteersCompletedNCT04033406Phase 1
- Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis BCompletedNCT03672188Phase 1/2